<DOC>
	<DOCNO>NCT01869166</DOCNO>
	<brief_summary>RATIONALE : Placing tumor antigen chimeric receptor create laboratory patient autologous T cell may make body build immune response kill cancer cell . PURPOSE : This clinical trial study genetically engineer lymphocyte therapy treat patient EGFR positive advanced/unresectable operation solid tumor , lung cancer , colorectal cancer，ovary cancer，cholangiocarcinoma，pancreatic cancer，renal carcinoma relapsed/metastatic tumor .</brief_summary>
	<brief_title>Treatment Chemotherapy Refractory EGFR ( Epidermal Growth Factor Receptor ) Positive Advanced Solid Tumors ( CART-EGFR )</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety feasibility chimeric antigen receptor T cell transduce anti-EGFR Lentivirus vector ( refer CART-EGFR cell ) . II . Determine duration vivo survival CART-EGFR cell . RT-PCR ( reverse transcription polymerase chain reaction ) analysis whole blood use detect quantify survival CART-EGFR CD3zeta : CD137 time . SECONDARY OBJECTIVES : I . For patient advanced， relapsed/metastatic cancer , measure anti-tumor response due CART-EGFR cell infusion . II . Estimate relative traffic CART-EGFR cell tumor bed . III . Determine cellular humoral host immunity develop murine anti-EGFR , assess correlation loss detectable CART-EGFR ( loss engraftment ) . IV . Determine relative subset CART-EGFR T cell ( Tcm , Tem , Treg ) . OUTLINE : Patients assign 1 group accord order enrollment . Patients receive anti-EGFR-CAR ( couple CD137 CD3 zeta signal domain ) Lentivirus vector-transduced autologous T cell 3-5 day absence unacceptable toxicity . After completion study treatment , patient follow intensively 6 month , every 3 month 2 year , annually thereafter 13 year . Estimate relative traffic CART-EGFR cell peripheral blood .</detailed_description>
	<criteria>1 . Chemotherapy refractory EGFRpositive nonsmall cell lung cancer , colorectal cancer liver metastasis , chemotherapy resistant relapse ovary cancerlung cancer , cholangiocarcinoma，pancreatic cancer，renal carcinoma relapsed/metastatic/unresectable operation tumors.the expression EGFR tumor 50 % . 2 . Relapsed patient antiEGFR use antibody kinase inhibitor therapy . 3 . Patients must 18 year age old . 4 . Patients must ECOG ( Eastern Cooperative Oncology Group ) performance status 02 . 5 . Patients must evidence adequate hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm3 . Platelet count great 100,000/mm3 . Hemoglobin great 10g/dl ( patient may receive transfusion meet parameter ) . Total bilirubin &lt; 1.5 time upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . 6 . Seronegative HIV antibody . 7 . Seronegative active hepatitis B , seronegative hepatitis C antibody . 8 . Patients must willing practice birth control four month follow treatment.NOTE : woman childbearing age must evidence negative pregnancy test . 9 . Patients must willing sign inform consent . 1 . Patients life expectancy le 12 month exclude . 2 . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated congestive heart failure ( &gt; New York Heart Association Class II ) , myocardial infarction within 6 month study exclude . 3 . Patients follow pulmonary function abnormality exclude : FEV ( forced expiratory volume ) , &lt; 30 % predict ; DLCO ( diffuse capacity lung carbon monoxide ) &lt; 30 % predict ( postbronchodilator ) ; Oxygen Saturation less 90 % room air . 4 . Patients severe liver kidney dysfunction consciousness disorder exclude . 5 . Pregnant and/or lactate woman exclude . 6 . Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor . 7 . Patients type primary immunodeficiency exclude study . 8 . Patients require corticosteroid ( inhale ) exclude . 9 . Patients history T cell tumor exclude . 10 . Patients participate participated clinical trial late 30 day exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>chemotherapy and/or EGFR-antibody/kinase inhibitor therapy refractory solid tumor</keyword>
</DOC>